Leerink Partnrs Analysts Lower Earnings Estimates for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Leerink Partnrs lowered their FY2025 earnings estimates for BioMarin Pharmaceutical in a note issued to investors on Tuesday, April 16th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will post earnings per share of $1.98 for the year, down from their prior estimate of $2.16. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $1.85 per share. Leerink Partnrs also issued estimates for BioMarin Pharmaceutical’s FY2026 earnings at $2.37 EPS.

A number of other research analysts have also issued reports on BMRN. Piper Sandler dropped their target price on BioMarin Pharmaceutical from $115.00 to $107.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. Stifel Nicolaus reissued a “buy” rating and issued a $101.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, December 21st. Royal Bank of Canada restated a “sector perform” rating and issued a $100.00 target price on shares of BioMarin Pharmaceutical in a research note on Friday, February 23rd. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $91.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, February 29th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $100.00 price target on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $107.61.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN stock opened at $90.47 on Thursday. BioMarin Pharmaceutical has a 52-week low of $76.02 and a 52-week high of $100.31. The stock’s 50-day moving average price is $87.57 and its 200 day moving average price is $89.11. The company has a quick ratio of 1.57, a current ratio of 2.51 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $17.07 billion, a PE ratio of 102.81, a price-to-earnings-growth ratio of 1.69 and a beta of 0.31.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. BioMarin Pharmaceutical had a net margin of 6.93% and a return on equity of 5.01%. The company had revenue of $646.21 million for the quarter, compared to the consensus estimate of $639.53 million. During the same period last year, the firm posted $0.11 EPS. BioMarin Pharmaceutical’s revenue for the quarter was up 20.2% on a year-over-year basis.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of hedge funds and other institutional investors have recently made changes to their positions in BMRN. Vanguard Group Inc. boosted its stake in BioMarin Pharmaceutical by 2.0% in the 4th quarter. Vanguard Group Inc. now owns 18,050,062 shares of the biotechnology company’s stock worth $1,740,387,000 after buying an additional 348,852 shares during the last quarter. Capital Research Global Investors boosted its position in shares of BioMarin Pharmaceutical by 79.0% in the fourth quarter. Capital Research Global Investors now owns 10,774,641 shares of the biotechnology company’s stock worth $1,038,907,000 after acquiring an additional 4,756,671 shares during the last quarter. Barclays PLC grew its holdings in BioMarin Pharmaceutical by 31.6% in the third quarter. Barclays PLC now owns 5,573,157 shares of the biotechnology company’s stock valued at $493,111,000 after purchasing an additional 1,336,886 shares during the period. Ameriprise Financial Inc. increased its position in BioMarin Pharmaceutical by 5.6% during the third quarter. Ameriprise Financial Inc. now owns 5,163,949 shares of the biotechnology company’s stock worth $456,906,000 after purchasing an additional 275,436 shares during the last quarter. Finally, Viking Global Investors LP raised its stake in BioMarin Pharmaceutical by 16.0% during the fourth quarter. Viking Global Investors LP now owns 4,889,454 shares of the biotechnology company’s stock worth $471,441,000 after purchasing an additional 673,998 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Insider Buying and Selling at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, Director Jean Jacques Bienaime sold 20,000 shares of the firm’s stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $91.26, for a total transaction of $1,825,200.00. Following the completion of the transaction, the director now directly owns 474,994 shares in the company, valued at approximately $43,347,952.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $91.26, for a total transaction of $1,825,200.00. Following the completion of the sale, the director now owns 474,994 shares in the company, valued at approximately $43,347,952.44. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Erin Burkhart sold 2,286 shares of BioMarin Pharmaceutical stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $90.00, for a total transaction of $205,740.00. Following the sale, the chief accounting officer now owns 16,156 shares of the company’s stock, valued at $1,454,040. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 103,229 shares of company stock valued at $9,062,967. Insiders own 1.84% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.